<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086731</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002985</org_study_id>
    <secondary_id>NCI-2021-09125</secondary_id>
    <secondary_id>EU5395-21</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT05086731</nct_id>
  </id_info>
  <brief_title>Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Non-Metastatic Triple Negative Breast Cancer</brief_title>
  <official_title>THRIVE Smart - Leveraging Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Non-Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates the feasibility and acceptability of a mobile health device in&#xD;
      improving oral chemotherapy adherence in women with triple negative breast cancer that has&#xD;
      not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT&#xD;
      smart pill bottle may help doctors to remind patients to take medicine on time and monitor&#xD;
      their symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Feasibility. II. Acceptability. III. Capecitabine/Xeloda adherence.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Symptom burden. II. Patent physician communication. III. Quality of life. IV.&#xD;
      Self-efficacy for managing symptoms.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive&#xD;
      reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda&#xD;
      treatment cycles.&#xD;
&#xD;
      GROUP II: Patients receive standard of care.&#xD;
&#xD;
      After completion of study, patients are followed up for 90 days after the initiation of&#xD;
      capecitabine/Xeloda.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>From baseline up to 90 days</time_frame>
    <description>Proportion of times each patient took her scheduled medication during the 3-month study. For each patient, will operationalize adherence as the number of times that the pill monitor recorded a dose taken for each day that the patient was in the study and supposed to take the pill. Days during which patients were off cycle, advised by their provider to temporarily stop the medication, or hospitalized will be deducted from the total days in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-user engagement by patients and their oncology team</measure>
    <time_frame>From baseline up to 90 days</time_frame>
    <description>Will measure patient's use of the smart pill bottle, their response to weekly symptoms text message questions, response to the smart reminders, and response to the adherence reason text message question. In addition, will also measure and evaluate the provider response to any adherence or symptom alerts triggered during the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>From baseline up to 90 days</time_frame>
    <description>Will be measured using survey questions about the intervention after the 90-day intervention. Acceptability and usability will be determined using the System Usability Scale.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptom burden</measure>
    <time_frame>From baseline up to 90 days</time_frame>
    <description>Will be measured using an adapted version of the National-Comprehensive Cancer Network Functional Assessment of Cancer Therapy Breast Cancer Symptom index (NCCN-FACT FBSI-16).</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-efficacy for managing symptoms</measure>
    <time_frame>From baseline up to 90 days</time_frame>
    <description>Will be measured by 4-item PROMIS Item Bank version 1.0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anatomic Stage I Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage II Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage III Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIC Breast Cancer AJCC v8</condition>
  <condition>Localized Breast Carcinoma</condition>
  <condition>Prognostic Stage I Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage II Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage III Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIC Breast Cancer AJCC v8</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (SMRxT smart pill bottle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a SMRxT smart pill bottle and standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard of care</description>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive reminders</description>
    <arm_group_label>Group I (SMRxT smart pill bottle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Device Usage and Evaluation</intervention_name>
    <description>Receive a SMRxT smart pill bottle</description>
    <arm_group_label>Group I (SMRxT smart pill bottle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (SMRxT smart pill bottle)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (SMRxT smart pill bottle)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Non-metastatic triple negative breast cancer&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  New or existing prescription for capecitabine/Xeloda who get it filled at the Emory&#xD;
             Specialty Pharmacy (within the first 3 cycles of use)&#xD;
&#xD;
          -  Willingness and ability of the subject to comply with study procedures&#xD;
&#xD;
          -  Have a mobile phone with text message&#xD;
&#xD;
          -  Evidence of an online informed consent indicating that the subject is aware of the&#xD;
             risk and benefits of study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who do not receive their capecitabine/Xeloda prescription until a month after&#xD;
             enrollment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilana Graetz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilana Graetz, PhD</last_name>
    <phone>404-727-1483</phone>
    <email>ilana.graetz@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Robles</last_name>
      <phone>404-727-1483</phone>
      <email>andrew.robles@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ilana Graetz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Robles</last_name>
      <phone>404-727-1483</phone>
      <email>andrew.robles@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ilana Graetz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Robles, MA</last_name>
      <phone>404-712-9604</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Ilana Graetz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

